Webinar
Webinar | Wednesday September 6, 2023 | 2:00 pm–3:00 pm CEST / 8:00 am–9:00 am EDT
Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the...
Verve Therapeutics recently announced the first human dosing with VERVE-101, an investigational base-editing therapy that is designed to treat...
Verve Therapeutics announced last week that its clinical trial application for VERVE-101 in heterozygous familial hypercholesterolemia had been...
Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics